I agree, increasing the share count is fine if it is to further trials etc, but when it is to keep the payroll going with no partnerships or trial catalysts it is kind of stupid. The clinical hold should never have happened and better be resolved before the annual meeting. They must get the hold lifted before the vote, other wise don’t ask for shares. Every time share count has been increased, it was to fund trials. We need to get our moneys worth first because we already paid for so much. We are long past the blame nader and Amarex phase, this management team needs to show results in there path by now.